Safety and Efficacy of Prolonged Use of Unfractionated Heparin After Percutaneous Coronary Intervention

被引:0
|
作者
Singh, Param Puneet [1 ]
Arora, Rohit
Singh, Mukesh
Bedi, Updesh Singh
Adigopula, Sasikanth
Singh, Sarabjeet
Bhuriya, Rohit
Molnar, Janos
Khosla, Sandeep
机构
[1] Rosalind Franklin Univ Med & Sci, Dept Internal Med, Chicago Med Sch, Cardiol Sect, N Chicago, IL 60064 USA
关键词
unfractionated heparin; prolonged infusion; post-percutaneous coronary intervention; PERIPHERAL VASCULAR COMPLICATIONS; ANGIOPLASTY; THERAPY; HEART; ANTICOAGULATION; ANTITHROMBIN; ASSOCIATION; TRIAL;
D O I
10.1097/MJT.0b013e3181b63f05
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current guidelines for percutaneous coronary intervention do not address the prolonged postprocedural use of unfractionated heparin (UFH) to prevent acute occlusion. However, recently published small studies have yielded mixed results, leaving the question unanswered. Hence, we performed a meta-analysis of the existing evidence to assess the safety and efficacy of prolonged infusion of UFH after percutaneous coronary intervention. A systematic review of literature revealed seven studies involving 2412 patients. End points analyzed were ischemic complications (acute closure, myocardial infarction, and repeat revascularization) and major vascular complications (hematoma, arteriovenous fistula, pseudoaneurysm, and retroperitoneal bleed). Because the studies were homogenous for outcomes, combined relative risks across all the studies and the 95% confidence intervals were computed using the Mantel-Haenszel fixed-effect model. A two-sided alpha error <0.05 was considered to be statistically significant. There were no significant differences in patient demographics between both groups. Compared with placebo, the risk of major vascular complication was significantly higher in patients getting postprocedural UFH for prolonged hours (relative risk, 2.24; confidence interval, 1.68-3.48; P = 0.001). However, the risk of ischemic complications was similar in both groups (relative risk, 0.95; confidence interval, 0.46-1.96; P = 0.89). The meta-analysis suggests that routine infusion of UFH after uncomplicated percutaneous coronary intervention may result in increased vascular complications without any reduction in incidence of ischemic complications.
引用
收藏
页码:535 / 542
页数:8
相关论文
共 50 条
  • [21] Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention
    Watson, Kristin
    Seybert, Amy L.
    Saul, Melissa I.
    Lee, Joon Sup
    Kane-Gill, Sandra L.
    PHARMACOTHERAPY, 2007, 27 (05): : 647 - 656
  • [22] Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial
    Montalescot, Gilles
    Gallo, Richard
    White, Harvey D.
    Cohen, Marc
    Steg, Gabriel
    Aylward, Philip E. G.
    Bode, Christoph
    Chiariello, Massimo
    King, Spencer B., III
    Harrington, Robert A.
    Desmet, Walter J.
    Macaya, Carlos
    Steinhubl, Steven R.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (11) : 1083 - 1091
  • [23] Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in Percutaneous Peripheral Intervention A Single-Center Experience
    Sheikh, Imran R.
    Ahmed, S. Hinan
    Mori, Naoyo
    Gupta, Anjan
    Mewissen, Mark
    Allaqaband, Suhail
    Bajwa, Tanvir
    JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (09) : 871 - 876
  • [24] Impact of Triple Antithrombotic Therapy on Amount of Unfractionated Heparin During Percutaneous Coronary Intervention
    Okamoto, Naotaka
    Shutta, Ryu
    Yasunaga, Motoki
    Yanagawa, Kyosuke
    Matsuhiro, Yutaka
    Nakamura, Hitoshi
    Yasumoto, Koji
    Yasumura, Keisuke
    Tanaka, Akihiro
    Mori, Naoki
    Nakamura, Daisuke
    Yano, Masamichi
    Makino, Nobuhiko
    Egami, Yasuyuki
    Nishino, Masami
    Tanouchi, Jun
    CIRCULATION, 2016, 134
  • [25] Impact of Triple Antithrombotic Therapy on Amount of Unfractionated Heparin During Percutaneous Coronary Intervention
    Okamoto, Naotaka
    Shutta, Ryu
    Yasunaga, Motoki
    Yanagawa, Kyosuke
    Matsuhiro, Yutaka
    Nakamura, Hitoshi
    Yasumoto, Koji
    Yasumura, Keisuke
    Tanaka, Akihiro
    Mori, Naoki
    Nakamura, Daisuke
    Yano, Masamichi
    Makino, Nobuhiko
    Egami, Yasuyuki
    Nishino, Masami
    Tanouchi, Jun
    CIRCULATION, 2016, 134
  • [26] Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention:: a randomized study
    Galeote, G
    Hussein, M
    Sobrino, N
    Calvo, L
    Yunda, H
    Sánchez-Recaide, A
    Sobrino, JA
    EUROPEAN HEART JOURNAL, 2001, 22 : 663 - 663
  • [27] THE EVALUATION OF ADMINISTERING A FIXED BOLUS OF UNFRACTIONATED HEPARIN PRIOR TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION
    Nosair, Mohamed
    Joyal, Dominique
    Eisenberg, Mark
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E476 - E476
  • [28] Early clinical benefit with bivalirudin compared to unfractionated heparin during percutaneous coronary intervention
    Mehran, R
    Aymong, E
    Moses, J
    Lansky, A
    Stone, G
    Leon, M
    Moussa, I
    Dangas, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (6A): : 134L - 134L
  • [29] Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
    Li Zhi-Zhong
    Tao Ying
    Wang Su
    Yin Cheng-Qian
    Gao Yu-Long
    Cheng Yu-Tong
    Li Zhao
    Ma Chang-Sheng
    中华医学杂志英文版, 2018, 131 (20) : 2417 - 2423
  • [30] Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
    Li, Zhi-Zhong
    Tao, Ying
    Wang, Su
    Yin, Cheng-Qian
    Gao, Yu-Long
    Cheng, Yu-Tong
    Li, Zhao
    Ma, Chang-Sheng
    CHINESE MEDICAL JOURNAL, 2018, 131 (20) : 2417 - 2423